Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
This real-world study highlights the considerable risk of recurrence with adjuvant ET in patients with stage II or III HR+/HER2- EBC (including node-negative disease) and confirms the need for improved treatment options.
Authors
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Murat Akdere (ORCID: https://orcid.org/0009-0001-4883-0463)
- Denise A. Yardley (ORCID: https://orcid.org/0000-0002-8664-3458)
- Pedram Razavi (ORCID: https://orcid.org/0000-0003-4236-0576)
- Joyce O’Shaughnessy (ORCID: https://orcid.org/0000-0002-2955-5523)
- Aamir Khakwani (ORCID: https://orcid.org/0000-0001-9257-1836)
- Purnima Pathak (ORCID: https://orcid.org/0000-0002-6225-9128)
- Stephanie L. Graff (ORCID: https://orcid.org/0000-0003-1928-1722)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Lee S. Schwartzberg (ORCID: https://orcid.org/0000-0002-7433-3428)
- Julia Kim (ORCID: https://orcid.org/0000-0002-3644-6560)
- Lowell L. Hart
- Courtney McDermott (ORCID: https://orcid.org/0000-0001-6294-868X)
- Wolfgang Janni
Institutions
- Novartis (Switzerland) (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Sarah Cannon Research Institute (GB)
- Universität Ulm (DE)
- Brown University (US)
- Baylor University Medical Center (US)
- Renown Health (US)
- Sarah Cannon (US)
- Dana-Farber Cancer Institute (US)
- Florida Cancer Specialists & Research Institute (US)
- Novartis (United Kingdom) (GB)
- Dana-Farber/Harvard Cancer Center (US)
- Genesis Research Institute (JP)
- Comprehensive Cancer Center Erlangen (DE)
- Novartis (Ireland) (IE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- The Breast
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1016/j.breast.2025.104437
- Citations
- 5
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.68
Funders
- Novartis Pharmaceuticals Corporation